Improving diagnosis of rectal cancer using imaging techniques

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to enhance the accuracy of diagnosing adenocarcinoma of the rectum by using MRI mapping techniques to identify and map tumor deposits before surgery. Radiologists will share this imaging information with pathologists to improve the concordance between imaging and pathology findings. The study is prospective and multi-centre, involving patients who are undergoing surgical resection for suspected primary adenocarcinoma. Participants will be followed for five years to assess the impact of this approach on treatment and prognosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Suspected primary adenocarcinoma of the colon, sigmoid or rectum (proven by biopsy taken as part of routine clinical practice, patients to be withdrawn if not subsequently adenocarcinoma on pathology).
2. Amenable to surgical resection.
3. Disease spread assessed on imaging
4. Patients having primary surgery and those undergoing neoadjuvant treatment will be included.
5. All must have had baseline staging scans and those undergoing neoadjuvant therapy must also have had a post-treatment scan.
6. Patients aged 16 years and over

Exclusion Criteria:

1. Patients with recurrent tumours
2. Synchronous tumours
3. Under the age of 16 years
4. Unable to give informed consent.

Where it's running

• Royal Marsden Hospital NHS Foundation Trust
  London, Surrey, United Kingdom Recruiting

Study contacts

• Principal investigator: Gina Brown, MD — Imperial College London
• Study coordinator: Caroline Martin
• Email: c.martin1@imperial.ac.uk
• Phone: +44 (0) 7749 655 817

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding how rectal cancer responds to standard treatment before surgery

  This study is testing how well standard treatments for rectal cancer work before surgery to see if they can help predict how the cancer will change.

  Recruiting at 6 sites Memorial Sloan Kettering Cancer Center · Middletown, New Jersey and 5 other locations · NCT06637462

• Combining Tucatinib and Trastuzumab for HER2 Positive Rectal Cancer

  This study is testing if combining two cancer drugs, tucatinib and trastuzumab, with standard chemotherapy can help people with HER2 positive rectal cancer have better treatment results.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05672524

• Comparing 5-year and 10-year colonoscopy schedules for patients with non-advanced adenomas

  This study is testing whether people with 1 to 2 non-advanced polyps can safely have colonoscopies every 10 years instead of every 5 years without raising their risk of colorectal cancer.

  Recruiting at 348 sites NRG Oncology · Fairbanks, Alaska and 498 other locations · NCT05080673

• Biopsy to study tumor changes after radioembolization

  This study is trying to see how tumors in patients with colorectal cancer that has spread to the liver change after they receive a specific radiation treatment called radioembolization.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York · NCT04668872

• Testing stool samples for cancer detection in colorectal cancer survivors

  This study is testing if a new stool test can help find polyps and cancer in colorectal cancer survivors to see if it works better than regular check-ups.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT04624555

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.